East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)

PURPOSE: REVEL demonstrated improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV non-small cell lung cancer patients with disease progression following platinum-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Keunchil, Kim, Joo-Hang, Cho, Eun Kyung, Kang, Jin-Hyoung, Shih, Jin-Yuan, Zimmermann, Annamaria Hayden, Lee, Pablo, Alexandris, Ekaterine, Puri, Tarun, Orlando, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080808/
https://www.ncbi.nlm.nih.gov/pubmed/26910471
http://dx.doi.org/10.4143/crt.2015.401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080808/
https://www.ncbi.nlm.nih.gov/pubmed/26910471
http://dx.doi.org/10.4143/crt.2015.401

Ejemplares similares